How Clinical Lab Operations Are Evolving for 2026 and Beyond

The year ahead marks a pivotal moment for the clinical laboratory. More and more, labs are leveraging automation and AI, enhancing collaboration and sustainability efforts, and advancing treatment options with precision medicine. Clinical labs are uniquely positioned to bring emerging scientific discoveries to the forefront, enhancing patient care.

Leaders at Thermo Fisher Scientific share their perspectives on how clinical lab operations are evolving for 2026 and beyond.

Advancing biological discovery with omics research

Ellie Mahjubi, MSTM, MBA, believes 2026 is poised to be a transformative year for biological innovation, defined by accelerated discoveries and a deeper focus on empowering the scientists behind them. 

Multi-omics and spatial methods will further open new windows into biology. The ability to analyze cells in their natural tissue environment will deepen our understanding of how the cellular landscape reflects the efficacy of novel treatments and the resultant patient outcomes. 

Together with breakthroughs in next-generation sequencing (NGS) and cryo-electron microscopy, laboratories will push the boundaries of biological insight, helping researchers ask deeper, more impactful questions.

Industry collaboration supporting the advancement of precision medicine 

In 2026, pharma and diagnostics teams will focus more on what real-world access actually looks like for patients. Jane Li believes we still have far too many people who qualify for targeted therapies but never receive them. Much of that comes down to practical issues—the test isn’t ordered, the tissue sample is too small, or the NGS results take too long to return. She expects more collaboration around the everyday hurdles that keep patients from getting tested. 

At the same time, testing needs are only growing. More drug assets are moving into early-stage cancers and targets like HER2 and pan-KRAS are now relevant across many solid tumors. That puts even more weight on rapid, reliable workflows. Scientists are also seeing new sample types and minimal residual disease (MRD) open the door to patients who weren’t typically tested before. 

The real opportunity for the year ahead lies in developing solutions that clinical teams can use in routine practice—tools that make cross-tumor tests truly meaningful and help close the gap between who's eligible for targeted treatments and who actually receives them.

Developments in post-transplant diagnostics care

According to Richard Knight, MD, new diagnostics solutions are emerging within the transplant diagnostics space to optimize immunosuppressant drug protocols following transplantation. 

Today, patients who receive a transplanted organ require lifelong immunosuppressant drug regimens, but these therapies are often prescribed using a “one-size-fits-all” approach. Because this model doesn’t consider key factors such as age, genetics, or existing comorbidities, this approach increases the risk of over-immunosuppression. 

New innovative transplant diagnostics solutions will enable clinicians to provide more personalized immunosuppression treatment regimens that account for a patient’s unique health profile, thereby reducing the risk of over-immunosuppression. 

We can also expect a shift toward less invasive and more precise monitoring solutions that aim to both improve transplant outcomes and quality of life for transplant recipients.

Sustainability efforts in the clinical lab 

Most scientific verticals are looking for ways to help improve sustainability efforts, and those efforts will only increase in the next year. Noreen Hong, MBA, believes that in 2026 and beyond, laboratories and suppliers across the life sciences industry will adopt more sustainable technologies and practices. From developing more energy-efficient laboratory equipment to enhancing recycling options for products and packaging, we can expect to see greener options at all stages of a product’s life cycle. 

Additionally, regulatory bodies around the world are enacting policies to shift toward more sustainable options for chemicals and products, which are impacting the lab. Some suppliers are already working to develop products that can help labs remain compliant with regulations, even as new, more sustainable policies are introduced. 

Transparency and clear sustainability goals will no longer be nice-to-haves, but will be expected for labs and suppliers to collaborate on a more sustainable future.

Leveraging next-generation technologies to streamline lab operations

Looking ahead, Misty Phillips, MLS(ASCP)MB, believes that clinical laboratories will be fully connected digital ecosystems, where AI, automation, and integrated systems streamline operations and enhance testing accuracy. Robotics, predictive maintenance, and automated quality control will reduce manual errors and downtime, while workflow-orchestration tools optimize turnaround times and resource allocation. 

These intelligent systems will support standardization, traceability, and reproducibility, reinforcing public trust in laboratory results. As technology reshapes daily workflows, laboratory professionals will take on more strategic and leadership-focused roles, supported by advocacy, continuous education, and sustainable staffing practices. 

Together, these advancements will create laboratories that are faster, more reliable, environmentally responsible, and ready to meet the increasing complexity and demands of modern health care.

A new era for the clinical lab

The future of the clinical lab will be led by new technologies and testing capabilities, widespread collaboration, and enhanced research that results in new scientific discoveries. Clinical lab teams must ensure they are engaging in sustainable practices as continued regulations emerge.

To develop better therapies and treatments for patients, omics research must continue to progress to put precision medicine into practice. Advancements in post-transplant diagnostics that enable more precise immunosuppressive care will also be critical to improving the patient experience. A recurring theme with omics research and transplant diagnostics, as well as with the use of next generation technologies like AI and automation, is precision, which will be a central theme in the clinical lab in the coming years.

Alongside the new technologies, testing abilities and research that aim to power more precision in the clinical lab, enacting more sustainable practices and more collaboration across teams will push the clinical lab to accelerate new discoveries.

Read More: 7 Emerging Trends Shaping Clinical Labs in 2026